Gregory A. Dekaban1, Xizhong Zhang2,
Vasiliki Economopoulos3, Jennifer Noad3, Roja Rohani3,
Adele Wang4, Megan Levings4, Ronan Foley5,
Paula Foster3
1BioTherapeutics Research Laboratory,
Robarts Research Institute, London , Ontario, Canada; 2BioTherapeutics
Research Laboratory, Robarts Research Institute, London, Ontario, Canada; 3Imaging
Research Laboratories, Robarts Research Institute; 4Department of
Surgery, University of British Columbia; 5Department of Pathology
and Molecular Medicine, McMaster University
The
successful migration of adequate numbers of in vitro-generated human
dendritic cells (DC) from the site of injection to a draining lymph node is a
necessary and crucial step in order for a DC-based vaccine to be a successful
immunotherapy for cancer and infectious disease. Currently, less than 5% of injected DC
migrate to a draining lymph node. How well a preparation of DC migrates is
best assessed by conducting migration assays in vivo. Here we demonstrated that migration of
human DC labeled with superparamagnetic iron oxide nanoparticles can be
tracked to lymph nodes of CB17 scid
mice.